Interested in specific Information?

Filter what you see here

General MM

Quick poll

MAIA study: second interim analysis results

MAIA study: second interim analysis results

Closes Dec 6, 2019

Relapsed/refractory patients

Quick poll

Ixazomib, thalidomide, and dexamethasone for relapsed/refractory multiple…

Closes Dec 4, 2019

General MM

Quick poll

Lenalidomide versus observation in patients with smoldering multiple…

Closes Nov 27, 2019 , Expert Opinion

Patients eligible for transplant

Quick poll

Expert Commentary | The impact of extramedullary disease on…

Expert Commentary | The impact of extramedullary disease on transplantation outcomes in multiple myeloma

Closes Nov 22, 2019

General MM

Quick poll

Response-adapted intensification with cyclophosphamide, bortezomib, and…

Closes Nov 20, 2019

General MM

Quick poll

IMW 2019 | Overview of novel cellular therapies in MM

Closes Nov 14, 2019

General MM

Quick poll

TOURMALINE-MM4 trial of ixazomib maintenance meets primary endpoint

TOURMALINE-MM4 trial of ixazomib maintenance meets primary endpoint

Closes Nov 13, 2019

Elderly patients

Quick poll

IMW 2019 | Management of elderly patients with multiple myeloma

Closes Nov 8, 2019 , Expert Opinion

Relapsed/refractory patients

Quick poll

TNB-383B receives Orphan Drug Designation from the U.S. FDA

Closes Nov 7, 2019 , Expert Opinion

Patients eligible for transplant

Quick poll

Monthly Educational Theme | Transplant in Myeloma

Monthly Educational Theme | Transplant in Myeloma

Closes Nov 6, 2019

Relapsed/refractory patients,   General MM

Quick poll

FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation…

Closes Nov 4, 2019

General MM

Quick poll

IMW 2019 | Results from the phase II PLEIADES trial (MMY2040): dara SC…

Closes Nov 1, 2019

Patients non-eligible for transplant

Quick poll

Daratumumab, lenalidomide and dexamethasone granted positive opinion by…

Daratumumab, lenalidomide and dexamethasone granted positive opinion by EMA CHMP

Closes Oct 23, 2019

Relapsed/refractory patients

Quick poll

IMW 2019 | OPTIMISMM: Subgroup analysis by prior exposure to bortezomib

Closes Oct 21, 2019

Relapsed/refractory patients

Quick poll

IMW 2019 | A.R.R.O.W.: Subgroup analysis by frailty score

Closes Oct 18, 2019 , Expert Opinion
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Relapsed/refractory patients

IMW 2019 | ICARIA-MM: Cytogenetic subgroup analysis

Oct 17, 2019 , Expert Opinion
Patients eligible for transplant

VRD induction for ASCT: Results from the phase III GEM2012/MENOS65 trial

Oct 17, 2019
General MM,   Relapsed/refractory patients

Bispecific antibodies in lymphoma, myeloma and acute myeloid leukemia

Oct 17, 2019 , Expert Opinion
Relapsed/refractory patients

TJ202 / MOR202 granted Investigational New Drug (IND) application in China

Oct 16, 2019 , Expert Opinion

Latest Congress Coverage

Latest Biology

Latest Drug Updates

Relapsed/refractory patients

TNB-383B receives Orphan Drug Designation from the U.S. FDA

Nov 7, 2019 , Expert Opinion
Relapsed/refractory patients

TJ202 / MOR202 granted Investigational New Drug (IND) application in China

Oct 16, 2019 , Expert Opinion

Recently updated Licenses

Where we are next

61st ASH Annual Meeting & Exposition

December 7-10, 2019 | Orange County Convention Center (OCCC), Orlando, FL

The Multiple Myeloma Hub will be attending the 61st ASH Annual Meeting & Exposition in Orange County Convention Center (OCCC), Orlando, FL. We will be presenting live coverage via our social media channels, interviewing world-leading experts and providing summaries of key sessions. Stay tuned to follow our first-hand coverage.

Use the following hashtags on Twitter to join the conversation: #mmsm

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology